Compared to PD-1/-L1 inhibitor monotherapy, PD-1/-L1 inhibitor plus CTLA-4 inhibitor was associated with increased risk of pruritus and rash [any grade pruritus RR:1.76 (95% CI 1.42-2.18, p < 0.00001) (Figure 6A), high grade pruritus RR: 6.05 (95% CI 1.17-31.33, p = 0.03) (Figure 6B), any grade rash RR:1.72 (95% CI 1.29-2.31, p = 0.0003) (Figure 6C), high grade rash RR:3.89 (95% CI 1.45-10.42, p = 0.007) (Figure 6D)]. This evidence concerns the gene PDCD1 and Pruritus.